Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Problem

Cancer prevalence is increasing, putting a strain on healthcare systems and impacting millions of lives. Traditional cancer treatments like tumor boards have limitations in time, place, and access to specialists.

Solution

Normax proposes the Educated Antigen Receptor Therapy (EARTh) GMP Process and Virtual Tumor Board(VTB) as innovative approaches to personalized cancer treatment.

EARTh GMP Process focuses on utilizing a patient’s own genetic information to develop targeted immunotherapies.

Overall, EARTh GMP Process offers a promising approach to personalized cancer immunotherapy with thepotential to improve patient outcomes and advance cancer treatment.

The Process

Patient Samples & Data

Tissue samples (healthy & cancerous) are collected from the patient with informed consent and undergo DNA sequencing.

AI-powered Analysis

Advanced AI tools process the DNA data to identify specific neoantigens (unique mutations) present inthe patient’s cancer cells.

mRNA Design & Production

The identified neoantigen sequences are used to design and print mRNA using technologies likeBioXP printer and DNA Script printer. This mRNA serves as the blueprint for personalized treatment.

Treatment Delivery

Two potential delivery methods are explored:

  • Lipid Nanoparticle (LNP) Delivery: The mRNA is encapsulated in LNPs for efficient delivery into the patient. The immune response can then recognize and attack cancer cells expressing the specific neoantigens.
  • Autologous Cell Transfusion Delivery: Patient’s T cells are extracted and “educated” with the mRNA outside the bodybefore being reintroduced via transfusion.

GMP Lab Testing

Before administration, the effectiveness of the personalized mRNA treatment is rigorously tested in a controlled lab environment to ensure safety and efficacy.

Benefits

Personalized Treatment

Tailored to each patient’s unique tumor profile, increasing the chances of successful treatment and minimizing side effects.

Advanced Technology

Leverages cutting-edge AI and mRNA technology for precise and efficient therapy development.

GMP Compliance

Adheres to Good Manufacturing Practices to ensure the quality and safety of the personalized treatment.

Join un in the future of AI empowered healthcare.

Contact

info@nrvx.net